Homocysteine increases tau phosphorylation, truncation and oligomerization

Norimichi Shirafuji, Tadanori Hamano, Shu Hui Yen, Nicholas M. Kanaan, Hirotaka Yoshida, Kouji Hayashi, Masamichi Ikawa, Osamu Yamamura, Masaru Kuriyama, Yasunari Nakamoto

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Increased plasma homocysteinemia is considered a risk factor of dementia, including Alzheimer’s disease (AD) and vascular dementia. However, the reason elevated plasma homocysteinemia increases the risk of dementia remains unknown. A pathological hallmark of AD is neurofibrillary tangles (NFTs) that consist of pathologically phosphorylated tau proteins. The effect of homocysteine (Hcy) on tau aggregation was explored using human neuroblastoma M1C cells that constitutively express human wild-type tau (4R0N) under the control of a tetracycline off system, primary mouse cultured neurons, and by inducing hyperhomocysteinemia in a mouse model of tauopathy (HHCy mice). A wide range of Hcy concentrations (10–1000 μM) increased total tau and phosphorylated tau protein levels. Hcy activated glycogen synthase kinase 3, and cyclin dependent kinase 5, major tau phosphokinases, and inactivated protein phosphatase 2A, a main tau phosphatase. Hcy exhibited cytotoxic effects associated with enhanced activation of caspase. Truncation of tau in the C-terminus, the cleavage site of caspase 3 (i.e., D421, detected by the TauC3 antibody) was also increased. Total tau, phosphorylated tau, as well as C-terminal cleaved tau were increased in the sarkosyl insoluble tau fraction. Hcy also increased the level of tau oligomers, as indicated by the tau oligomer complex 1 (TOC1) antibody that specifically identifies oligomeric tau species, in the tris insoluble, sarkosyl soluble fraction. The levels of TOC1-positive oligomeric tau were increased in brain lysates from HHCy mice, and treating HHCy mice with Sadenosylmethionine, an intermediate of Hcy, reduced the levels of oligomeric tau to control levels. These observations suggest that Hcy increases the levels of phosphorylated tau as well as truncated tau species via caspase 3 activation, and enhanced tau oligomerization and aggregation.

Original languageEnglish (US)
Article number891
JournalInternational Journal of Molecular Sciences
Volume19
Issue number3
DOIs
StatePublished - Mar 17 2018

Fingerprint

Oligomerization
phosphorylation
Phosphorylation
Homocysteine
Oligomers
Phosphatases
mice
Proteins
Antibodies
Agglomeration
Chemical activation
approximation
oligomers
Plasmas
phosphatases
Level control
tau Proteins
Alzheimer Disease
proteins
antibodies

Keywords

  • Alzheimer’s disease
  • Caspase 3
  • Cyclin dependent kinase5
  • Folate
  • Glycogen synthase kinase 3
  • Homocysteine
  • Oligomeric tau
  • Protein phosphatase 2A
  • Sadenosylmethionine
  • Tau
  • Vitamin B
  • Vitamin B

ASJC Scopus subject areas

  • Catalysis
  • Molecular Biology
  • Spectroscopy
  • Computer Science Applications
  • Physical and Theoretical Chemistry
  • Organic Chemistry
  • Inorganic Chemistry

Cite this

Shirafuji, N., Hamano, T., Yen, S. H., Kanaan, N. M., Yoshida, H., Hayashi, K., ... Nakamoto, Y. (2018). Homocysteine increases tau phosphorylation, truncation and oligomerization. International Journal of Molecular Sciences, 19(3), [891]. https://doi.org/10.3390/ijms19030891

Homocysteine increases tau phosphorylation, truncation and oligomerization. / Shirafuji, Norimichi; Hamano, Tadanori; Yen, Shu Hui; Kanaan, Nicholas M.; Yoshida, Hirotaka; Hayashi, Kouji; Ikawa, Masamichi; Yamamura, Osamu; Kuriyama, Masaru; Nakamoto, Yasunari.

In: International Journal of Molecular Sciences, Vol. 19, No. 3, 891, 17.03.2018.

Research output: Contribution to journalArticle

Shirafuji, N, Hamano, T, Yen, SH, Kanaan, NM, Yoshida, H, Hayashi, K, Ikawa, M, Yamamura, O, Kuriyama, M & Nakamoto, Y 2018, 'Homocysteine increases tau phosphorylation, truncation and oligomerization', International Journal of Molecular Sciences, vol. 19, no. 3, 891. https://doi.org/10.3390/ijms19030891
Shirafuji, Norimichi ; Hamano, Tadanori ; Yen, Shu Hui ; Kanaan, Nicholas M. ; Yoshida, Hirotaka ; Hayashi, Kouji ; Ikawa, Masamichi ; Yamamura, Osamu ; Kuriyama, Masaru ; Nakamoto, Yasunari. / Homocysteine increases tau phosphorylation, truncation and oligomerization. In: International Journal of Molecular Sciences. 2018 ; Vol. 19, No. 3.
@article{eaebae10dff44a7bb154ab125fe1d5da,
title = "Homocysteine increases tau phosphorylation, truncation and oligomerization",
abstract = "Increased plasma homocysteinemia is considered a risk factor of dementia, including Alzheimer’s disease (AD) and vascular dementia. However, the reason elevated plasma homocysteinemia increases the risk of dementia remains unknown. A pathological hallmark of AD is neurofibrillary tangles (NFTs) that consist of pathologically phosphorylated tau proteins. The effect of homocysteine (Hcy) on tau aggregation was explored using human neuroblastoma M1C cells that constitutively express human wild-type tau (4R0N) under the control of a tetracycline off system, primary mouse cultured neurons, and by inducing hyperhomocysteinemia in a mouse model of tauopathy (HHCy mice). A wide range of Hcy concentrations (10–1000 μM) increased total tau and phosphorylated tau protein levels. Hcy activated glycogen synthase kinase 3, and cyclin dependent kinase 5, major tau phosphokinases, and inactivated protein phosphatase 2A, a main tau phosphatase. Hcy exhibited cytotoxic effects associated with enhanced activation of caspase. Truncation of tau in the C-terminus, the cleavage site of caspase 3 (i.e., D421, detected by the TauC3 antibody) was also increased. Total tau, phosphorylated tau, as well as C-terminal cleaved tau were increased in the sarkosyl insoluble tau fraction. Hcy also increased the level of tau oligomers, as indicated by the tau oligomer complex 1 (TOC1) antibody that specifically identifies oligomeric tau species, in the tris insoluble, sarkosyl soluble fraction. The levels of TOC1-positive oligomeric tau were increased in brain lysates from HHCy mice, and treating HHCy mice with Sadenosylmethionine, an intermediate of Hcy, reduced the levels of oligomeric tau to control levels. These observations suggest that Hcy increases the levels of phosphorylated tau as well as truncated tau species via caspase 3 activation, and enhanced tau oligomerization and aggregation.",
keywords = "Alzheimer’s disease, Caspase 3, Cyclin dependent kinase5, Folate, Glycogen synthase kinase 3, Homocysteine, Oligomeric tau, Protein phosphatase 2A, Sadenosylmethionine, Tau, Vitamin B, Vitamin B",
author = "Norimichi Shirafuji and Tadanori Hamano and Yen, {Shu Hui} and Kanaan, {Nicholas M.} and Hirotaka Yoshida and Kouji Hayashi and Masamichi Ikawa and Osamu Yamamura and Masaru Kuriyama and Yasunari Nakamoto",
year = "2018",
month = "3",
day = "17",
doi = "10.3390/ijms19030891",
language = "English (US)",
volume = "19",
journal = "International Journal of Molecular Sciences",
issn = "1661-6596",
publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",
number = "3",

}

TY - JOUR

T1 - Homocysteine increases tau phosphorylation, truncation and oligomerization

AU - Shirafuji, Norimichi

AU - Hamano, Tadanori

AU - Yen, Shu Hui

AU - Kanaan, Nicholas M.

AU - Yoshida, Hirotaka

AU - Hayashi, Kouji

AU - Ikawa, Masamichi

AU - Yamamura, Osamu

AU - Kuriyama, Masaru

AU - Nakamoto, Yasunari

PY - 2018/3/17

Y1 - 2018/3/17

N2 - Increased plasma homocysteinemia is considered a risk factor of dementia, including Alzheimer’s disease (AD) and vascular dementia. However, the reason elevated plasma homocysteinemia increases the risk of dementia remains unknown. A pathological hallmark of AD is neurofibrillary tangles (NFTs) that consist of pathologically phosphorylated tau proteins. The effect of homocysteine (Hcy) on tau aggregation was explored using human neuroblastoma M1C cells that constitutively express human wild-type tau (4R0N) under the control of a tetracycline off system, primary mouse cultured neurons, and by inducing hyperhomocysteinemia in a mouse model of tauopathy (HHCy mice). A wide range of Hcy concentrations (10–1000 μM) increased total tau and phosphorylated tau protein levels. Hcy activated glycogen synthase kinase 3, and cyclin dependent kinase 5, major tau phosphokinases, and inactivated protein phosphatase 2A, a main tau phosphatase. Hcy exhibited cytotoxic effects associated with enhanced activation of caspase. Truncation of tau in the C-terminus, the cleavage site of caspase 3 (i.e., D421, detected by the TauC3 antibody) was also increased. Total tau, phosphorylated tau, as well as C-terminal cleaved tau were increased in the sarkosyl insoluble tau fraction. Hcy also increased the level of tau oligomers, as indicated by the tau oligomer complex 1 (TOC1) antibody that specifically identifies oligomeric tau species, in the tris insoluble, sarkosyl soluble fraction. The levels of TOC1-positive oligomeric tau were increased in brain lysates from HHCy mice, and treating HHCy mice with Sadenosylmethionine, an intermediate of Hcy, reduced the levels of oligomeric tau to control levels. These observations suggest that Hcy increases the levels of phosphorylated tau as well as truncated tau species via caspase 3 activation, and enhanced tau oligomerization and aggregation.

AB - Increased plasma homocysteinemia is considered a risk factor of dementia, including Alzheimer’s disease (AD) and vascular dementia. However, the reason elevated plasma homocysteinemia increases the risk of dementia remains unknown. A pathological hallmark of AD is neurofibrillary tangles (NFTs) that consist of pathologically phosphorylated tau proteins. The effect of homocysteine (Hcy) on tau aggregation was explored using human neuroblastoma M1C cells that constitutively express human wild-type tau (4R0N) under the control of a tetracycline off system, primary mouse cultured neurons, and by inducing hyperhomocysteinemia in a mouse model of tauopathy (HHCy mice). A wide range of Hcy concentrations (10–1000 μM) increased total tau and phosphorylated tau protein levels. Hcy activated glycogen synthase kinase 3, and cyclin dependent kinase 5, major tau phosphokinases, and inactivated protein phosphatase 2A, a main tau phosphatase. Hcy exhibited cytotoxic effects associated with enhanced activation of caspase. Truncation of tau in the C-terminus, the cleavage site of caspase 3 (i.e., D421, detected by the TauC3 antibody) was also increased. Total tau, phosphorylated tau, as well as C-terminal cleaved tau were increased in the sarkosyl insoluble tau fraction. Hcy also increased the level of tau oligomers, as indicated by the tau oligomer complex 1 (TOC1) antibody that specifically identifies oligomeric tau species, in the tris insoluble, sarkosyl soluble fraction. The levels of TOC1-positive oligomeric tau were increased in brain lysates from HHCy mice, and treating HHCy mice with Sadenosylmethionine, an intermediate of Hcy, reduced the levels of oligomeric tau to control levels. These observations suggest that Hcy increases the levels of phosphorylated tau as well as truncated tau species via caspase 3 activation, and enhanced tau oligomerization and aggregation.

KW - Alzheimer’s disease

KW - Caspase 3

KW - Cyclin dependent kinase5

KW - Folate

KW - Glycogen synthase kinase 3

KW - Homocysteine

KW - Oligomeric tau

KW - Protein phosphatase 2A

KW - Sadenosylmethionine

KW - Tau

KW - Vitamin B

KW - Vitamin B

UR - http://www.scopus.com/inward/record.url?scp=85044186536&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85044186536&partnerID=8YFLogxK

U2 - 10.3390/ijms19030891

DO - 10.3390/ijms19030891

M3 - Article

VL - 19

JO - International Journal of Molecular Sciences

JF - International Journal of Molecular Sciences

SN - 1661-6596

IS - 3

M1 - 891

ER -